References
- GopalSLiuYAlphsLSavitzANuamahIHoughDIncidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studiesNeuropsychiatr Dis Treat201391381139224092977
- LeoRJRegnoPDAtypical Antipsychotic Use in the Treatment of Psychosis in Primary CarePrim Care Companion J Clin Psychiatry20002619420415014629
- BarnesTRMcphillipsMACritical analysis and comparison of the side-effect and safety profiles of the new antipsychoticsBr J Psychiatry Suppl199938383443
- Invega Sustenna™ Prescribing Information2015 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207946s000lbl.pdfAccessed August 17, 2017
- Invega Trinza™ Prescribing Information2015 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207946s000lbl.pdf.Accessed August 17, 2017
- Trevicta [homepage on the Internet]Summary of Product Characteristics Available from: https://www.medicines.org.uk/emc/product/7230/smpcAccessed August 17, 2017
- CarpinielloBPinnaFCritical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophreniaDrug Des Devel Ther20161017311742
- RavenstijnPRemmerieBSavitzAPharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label studyJ Clin Pharmacol201656333033926189570
- BerwaertsJLiuYGopalSEfficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical TrialJAMA Psychiatry201572883083925820612
- SavitzAJXuHGopalSEfficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority StudyInt J Neuropsychopharmacol2016197pyw01826902950
- GopalSVijapurkarULimPMorozovaMEerdekensMHoughDA 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophreniaJ Psychopharmacol201125568569720615933
- HoughDGopalSVijapurkarULimPMorozovaMEerdekensMPaliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled studySchizophr Res20101162–310711719959339
- MarcusSCZummoJPettitARStoddardJDoshiJAAntipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital DischargeJ Manag Care Spec Pharm201521975476926308223
- PandinaGJLindenmayerJPLullJA randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophreniaJ Clin Psychopharmacol201030323524420473057
- ZhangFSiTChiouCFEfficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophreniaNeuropsychiatr Dis Treat20151165766825792835
- ChaDSMcintyreRSTreatment-emergent adverse events associated with atypical antipsychoticsExpert Opin Pharmacother201213111587159822304541
- MagnussonMOSamtaniMNPlanELPopulation Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with SchizophreniaClin Pharmacokinet201756442143327743205
- SamtaniMNVermeulenAStuyckensKPopulation pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychoticClin Pharmacokinet200948958560019725593
- FuDJTurkozISimonsonRBPaliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorderJ Clin Psychiatry201576325326225562685
- KastenMBrüggemannNKönigIRRisk for antipsychotic-induced extrapyramidal symptoms: influence of family history and genetic susceptibilityPsychopharmacology2011214372973621072501
- LencerREismannGKastenMFamily history of primary movement disorders as a predictor for neuroleptic-induced extrapyramidal symptomsBr J Psychiatry200418546547115572736
- PotvinSBlanchetPStipESubstance abuse is associated with increased extrapyramidal symptoms in schizophrenia: a meta-analysisSchizophr Res20091132–318118819608386